Ted Pharmaceuticals President Sun Yuhang: for the vast number of surgical patients to provide better drug use options

On December 22, 2020, Beijing Ted Pharmaceutical Co., Ltd. independently developed the muscular pine drug benzodiazean aquco ammonium injection (commodity name: Detai'an) officially obtained the drug approval number issued by the State Drug Administration of the People's Republic of China (approval number: national drug code H20203696), and as through the evaluation of the quality and efficacy of generic drugs, for the first pharmaceutical enterprises in the country through consistent evaluation, belongs to the national medical insurance catalogue.
Benzene Shun Aquku ammonium is a medium-acting, non-depolarized skeletal muscle relaxant with a pyrethroid structure that can be used as an all-hemp-assisted medication or as a sedative in the intensive care unit (ICU).
Benzene shun aquco ammonium with rapid effect, no cardiovascular side effects, no accumulation effect, a wide range of applications, suitable for the elderly, children, heart and liver and kidney dysfuncation and other special patients, as well as ICU patients, etc. , become a more ideal muscle relaxant.
in 2019, benzodiaxane Aquku ammonium accounted for more than 70% of the market share in the field of muscular pine medicine, the market size reached nearly 3 billion yuan, can be described as a leader in the muscular muffin drug market.
with the increasing number of domestic surgical patients and operating table, the market space for this variety in the field of surgical anesthesia may be further enhanced, the market potential is huge.
" the approved variety will strengthen and enrich Ted Pharmaceuticals' product pipeline in the field of surgical anesthesia analgesia.
future, Ted Pharmaceuticals will continue to provide a better choice of medication for the vast number of surgical patients! Sun Yuhang, president of Ted Pharmaceuticals, said.
Sun Yuhang told reporters that Ted Pharmaceuticals will spend 8% of its annual sales revenue on research and development innovation, has become the national leader in pharmaceutical research and development.
company around the new mechanism of innovative drugs, biological products, high-end preparations, high-end medical devices four business sectors, the development of domestic and even the world's leading innovative series of products, focusing on microcirculation, analgesics, respiratory, tumor four areas, with 300 patent applications for inventions, including pcT international patent applications more than 100.